Description
An inhibitor of ACC1 and ACC2 (IC50s = 2.1 and 6.1 nM, respectively, for the human enzymes); inhibits ACC dimerization; selective for ACC over 101 enzymes, receptors, growth factors, transporters, and ion channels up to a concentration of 10 µM; reduces fatty acid synthesis in HepG2 cells (EC50s = 66 and 9 nM in 10% FBS and serum-free media, respectively); reduces hepatic steatosis, improves glucose-stimulated insulin secretion, and reduces hemoglobin A1c levels by 0.9% in Zucker diabetic rats
Formal name: 1,4-dihydro-1-[(2R)-2-(2-methoxyphenyl)-2-[(tetrahydro-2H-pyran-4-yl)oxy]ethyl]-α,α,5-trimethyl-6-(2-oxazolyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-3(2H)-acetic acid
Synonyms: Firsocostat|GS-0976
Molecular weight: 569.6
CAS: 1434635-54-7
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|NAFLD & NASH||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Obesity
